CN Patent

CN112426424A — 一种egfr/her2受体酪氨酸激酶抑制剂在制备治疗her2突变癌症药物中的用途

Assigned to Jiangsu Hengrui Medicine Co Ltd · Expires 2021-03-02 · 5y expired

What this patent protects

本发明涉及一种EGFR/HER2受体酪氨酸激酶抑制剂在制备治疗HER2突变癌症药物中的用途。具体而言涉及式A所示化合物或其可药用盐在制备治疗HER2突变的癌症的药物中的用途。

USPTO Abstract

本发明涉及一种EGFR/HER2受体酪氨酸激酶抑制剂在制备治疗HER2突变癌症药物中的用途。具体而言涉及式A所示化合物或其可药用盐在制备治疗HER2突变的癌症的药物中的用途。

Drugs covered by this patent

bosutinib-monohydrate (BOSUTINIB MONOHYDRATE)

Patent Metadata

Patent number: CN112426424A
Jurisdiction: CN
Classification: —
Expires: 2021-03-02
Drug substance claim: No
Drug product claim: No
Assignee: Jiangsu Hengrui Medicine Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.